Android Artificial Pancreas System (AAPS) improves T1D glycemic control and quality of life.

Managing Type 1 Diabetes Mellitus (T1D) demands precise insulin delivery and continuous glucose monitoring to prevent hypo/hyperglycemia. Traditional methods often lead to suboptimal glycemic control and reduced quality of life. While commercial automated insulin delivery (AID) systems offer significant benefits, their high cost and limited availability pose substantial barriers, particularly in developing regions. This study addresses the critical need for accessible, low-cost solutions to expand automated therapy access globally.

Researchers conducted a survey-based study involving 371 Brazilian participants with Type 1 Diabetes (T1D). The cohort included 62 users of the Android Artificial Pancreas System (AAPS) and 309 non-users. The AAPS setup integrated continuous glucose monitoring (CGM), a MiaoMiao Bluetooth transmitter, and a non-automated insulin pump. Primary endpoints assessed were Time in Range (TIR), HbA1c levels, incidence of severe hypoglycemic events, and patient-reported quality of life.

AAPS users demonstrated significant improvements in glycemic control. Their mean Time in Range (TIR) was 78.5% ± 16.6. Crucially, HbA1c levels in AAPS users decreased from 7.3% ± 1.03 to 6.5% ± 0.7 (p < 0.001).

Compared to non-AAPS users, the AAPS group exhibited superior glycemic control, a statistically significant reduction in severe hypoglycemic events (p = 0.006), and markedly improved quality of life (p < 0.0001). However, the study also identified areas for improvement: 23.08% of AAPS users did not meet the recommended TIR target of 70%, and their time spent in level-2 hypoglycemia exceeded established guidelines, suggesting ongoing risks despite overall benefits.